Overcoming Barriers to Specialty Medication Adherence With CareTria
CareTria’s CEO Willis Chandler told Pharmaceutical Commerce that 50% of patients abandon specialty drugs due to fragmented support and lengthy benefit verification. The company’s automated platform unifies provider, pharmacy, and payer workflows, slashing the time from prescription to therapy from weeks to days. Chandler also highlighted emerging direct‑to‑patient cash programs and multimodal fulfillment as ways to sidestep payer bottlenecks. These innovations aim to improve adherence, patient outcomes, and pharmaceutical brand performance.
Brightseed Launches Enterprise AI Solution to Streamline Formulation and Manufacturing Success
Brightseed unveiled the world’s first clinically validated enterprise AI platform, designed to unite discovery, development, and commercialization for health‑science products. The system targets the industry’s 75% early‑stage failure rate by eliminating fragmented workflows and late‑stage risk discovery. Powered by the...
Nordic Cold Chain Solutions Launches Lab to Meet GLP-1 Demand
Nordic Cold Chain Solutions (NCCS) has opened a GLP‑1 & Small‑Format Packaging Innovation Lab to help pharmaceutical manufacturers, specialty pharmacies and e‑commerce players manage temperature‑sensitive drugs. The lab provides end‑to‑end services from early‑stage design and pilot testing to high‑volume production,...
Job Opportunity: HPM Seeks Associate Drug Development Attorney
Hyman, Phelps & McNamara (HPM) announced a vacancy for a 3rd‑to‑6th year associate attorney on its drug development team. The role supports clients through the full FDA pre‑market lifecycle, from pre‑IND strategy to IND, NDA/BLA submissions and dispute resolution. Candidates...
Pharma Pulse: Commercial Risks of the NDC-12 Transition and FDA Approval of Avlayah for Hunter Syndrome
The pharmaceutical industry faces commercial risk as it prepares for the 2033 transition to a uniform 12‑digit NDC format, with experts warning that thousands of zero‑prefix collisions could trigger PBM claim rejections, disrupt patient‑hub enrollments, and corrupt market‑intelligence data. Simultaneously,...
How Anesthetics Destabilize the Brain: Scientists Stumble upon Common Mechanism
MIT researchers discovered that three widely used anesthetics—propofol, ketamine and dexmedetomidine—produce an identical destabilization of brain dynamics, measurable as a loss of dynamic stability. Using EEG‑based perturbation analysis, they showed that despite distinct molecular targets, each drug pushes the brain...
Agenus to Host March 2026 Stakeholder Webcast Harnessing the Immune System to Advance BOT + BAL Across Tumor Types and...
Agenus announced a March 31, 2026 stakeholder webcast to detail progress on its botensilimab and balstilimab (BOT + BAL) immunotherapy program. The company highlighted clinical durability across multiple tumor types, with roughly 1,200 patients treated with botensilimab and over 900 with balstilimab...
Frank Harrell on Why and How to Do Bayes for Clinical Trials and the Recent FDA Draft Guidelines
Frank Harrell, a former FDA statistician, responded to recent JAMA commentary on the agency’s draft guidance promoting Bayesian methods for clinical trials. He highlighted that while the guidance is a step forward, FDA reviewers still rely on traditional frequentist approaches...
Pharmaceutical Executive Daily: Trump Administration Misses Deadline to Nominate Permanent CDC Director
The Trump administration failed to meet the 210‑day deadline to nominate a permanent CDC director, leaving the agency without confirmed leadership for most of the second term. Meanwhile, the FDA granted accelerated approval to Denali Therapeutics’ Avlayah, the first enzyme...
Cellular Senescence and Senotherapeutics: The Expert Roundup
Cellular senescence has become a focal point for longevity medicine, prompting a surge of senolytic and senomorphic drug development. Pioneering studies showed that clearing senescent cells can extend healthspan, leading biotech firms like Rubedo, SENISCA, Deciduous Therapeutics, and Arda Therapeutics...
Development of an Ultra-Sensitive Human Cardiac Troponin I Sandwich ELISA
Exazym®'s BOLD amplification technology boosts the sensitivity of a human cardiac troponin I sandwich ELISA by 180‑fold, lowering the detection limit to 0.07 pg/mL. The webinar presented by Cavidi’s Peter Stenlund shows how the method integrates into standard ELISA workflows with...
Autoimmune Immunotherapy Is Shifting Upstream: AnaptysBio on Targeting Pathogenic Immune Cells
Autoimmune drug development is moving upstream, targeting pathogenic immune cells rather than single cytokines. AnaptysBio’s Chief Medical Officer, Paul Lizzul, highlighted the company’s cell‑selective immunomodulation strategy, including CD122 antagonism that modulates both CD4 helper and CD8 cytotoxic T cells. Early‑phase...
Breaking: Senator Ron Johnson's Investigative Subcommittee Letter Submitted as Supplemental Authority in Sansone V. DeSantis mRNA Bioweapons Case
Dr. Joseph Sansone has filed Senator Ron Johnson’s investigative subcommittee letter as supplemental authority in his appellate lawsuit against Florida Governor Ron DeSantis and Attorney General James Uthmeier, alleging that mRNA COVID‑19 injections function as biological weapons. The filing cites...
Psilocybin Treatments for Treatment-Resistant Depression with Compass Pathways’ Dr. Steve Levine — Episode 248
The Xtalks Life Science Podcast featured Dr. Steve Levine, Chief Patient Officer at Compass Pathways, discussing the company’s push to develop psilocybin‑based therapies for treatment‑resistant depression (TRD). Levine, a board‑certified psychiatrist and founder of Actify Neurotherapies, highlighted the clinical promise...
Pharmaceutical Executive Daily: FDA Issues Warning Letter to ImmunityBio
The FDA issued a warning letter to ImmunityBio for misleading promotional claims about its bladder‑cancer drug Anktiva, triggering a roughly 26 percent drop in the company’s shares and giving it 15 days to submit a corrective plan. In parallel, Merck announced a...
BREAKING: Senate Investigation Finds Federal Officials Buried COVID-19 Vaccine Stroke Risk
A Senate investigation led by Sen. Ron Johnson uncovered that federal health officials identified a statistically significant ischemic stroke risk associated with the Pfizer COVID‑19 booster for adults 65 and older as early as November 2022. Internal HHS records show...
BREAKING STUDY: COVID-19 “Vaccines” DISRUPT THE BLOOD-BRAIN BARRIER — 63 Serious Brain & Spinal Cord Safety Signals Identified
A recent Substack post cites a study claiming COVID‑19 mRNA vaccines increase reports of rare neurological disorders by dozens to thousands of times compared with flu shots, based on VAERS data from 1990‑2024. The post lists specific conditions such as...
Two Polyunsaturated Lipids Demonstrate Senolytic Activity
Researchers identified two conjugated polyunsaturated fatty acids, α‑eleostearic acid (α‑ESA) and its methyl ester (α‑ESA‑me), as potent senolytics that selectively eliminate senescent cells. In mouse models, short‑term dosing reduced senescence markers and SASP factors across liver, heart, kidney, and lung...
Fujitsu and University of Osaka Develop New Tech for Chemical Material Energy Calculations on Early-FTQC Quantum Computers
Fujitsu and the University of Osaka have unveiled a new technology that couples the third version of Fujitsu’s STAR quantum architecture with a novel molecular model optimization technique. The combined approach dramatically lowers the quantum resources needed for chemical energy...
An Indication Selection Resource for Longevity Companies
Norn Group has released a free, detailed spreadsheet that maps 47 age‑related disease indications, providing mechanisms, incidence, market size, clinical endpoints, animal models, and trial cost estimates. The guide is designed to help longevity‑focused startups choose FDA‑approved disease targets rather...
Pharma M&A Roundup: Merck to Acquire Terns Pharmaceuticals, Shionogi to Acquire 50% of Apnimed’s Ownership of Shionogi-Apnimed Sleep Science
Merck announced a $6.7 billion cash deal to acquire Terns Pharmaceuticals, paying a 31% premium and targeting the oral BCR::ABL1 inhibitor TERN‑701 for treatment‑resistant chronic myeloid leukemia. The transaction, slated to close in Q2 2026, adds an orphan‑drug‑designated oncology asset to Merck’s...
How GLP-1 Agonists Affect Gene Expression and Promote Pancreatic Health
Researchers at the Salk Institute identified the protein Med14 as the molecular bridge that links GLP‑1 agonist drugs to broad genomic responses that enhance pancreatic beta‑cell health. The team showed that phosphorylation of Med14 is essential for activating gene programs...
Cybin Inc (HELP) Reports Positive Phase 2 Anxiety Study Data
Cybin Inc. announced topline results from a Phase 2 trial of its anxiety drug candidate HLP004, showing a 10‑point reduction on a standard anxiety rating scale. The study involved 36 patients already on antidepressants, and the benefit persisted for at least...
U.S. FDA Approves Label Update to Accelerate Thaw Time for ADSTILADRIN® (Nadofaragene Firadenovec-Vncg)
The U.S. FDA has approved a label update for Ferring Pharmaceuticals' ADSTILADRIN® (nadofaragene firadenovec‑vncg) that permits an accelerated water‑bath thawing process completed in roughly 25 minutes. The therapy, the only FDA‑approved non‑replicating intravesical gene‑therapy for high‑risk BCG‑unresponsive non‑muscle invasive bladder...
Syneos Health Expands China Operations with Bestudy CRO Acquisition
Syneos Health completed the acquisition of Shanghai‑based Bestudy Medical Technology on March 20, 2026, adding a fast‑growing Chinese CRO to its global network. Financial terms were not disclosed, and Bestudy will continue operating independently under its own brand. The deal...
BMS’ Sotyktu Receives FDA Expansion in Psoriatic Arthritis
Bristol Myers Squibb received FDA approval expanding Sotyktu (deucravacitinib) to treat adults with active psoriatic arthritis, making it the first oral selective TYK2 inhibitor for this indication. The label extension is backed by the POETYK PsA-1 and PsA-2 trials, where...
BioAge Labs Provides Business Updates
BioAge Labs reported full‑year 2025 results, highlighting positive Phase 1 data for its oral NLRP3 inhibitor BGE‑102, which achieved up to 86% reduction in hsCRP and strong suppression of IL‑1β, IL‑6, and fibrinogen. The company announced a Phase 2a cardiovascular risk trial...
How Pharma Supply Chains Can Brace for FDA’s 12-Digit NDC Standard
The FDA issued a final rule on March 5, 2026 establishing a uniform 12‑digit National Drug Code (NDC) that will replace the current variable 10‑digit format, with an effective date of March 7, 2033 and a seven‑year preparation window followed by a three‑year transition...
Amylyx Pharmaceuticals Announces Completion of Enrollment in Pivotal Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia
Amylyx Pharmaceuticals announced that the pivotal Phase 3 LUCIDITY trial of avexitide has completed enrollment, randomizing and dosing the final participant to bring the total to 78 patients across 21 U.S. sites. The double‑blind, placebo‑controlled study evaluates avexitide, a first‑in‑class GLP‑1...
Mosaic Therapeutics to Present Poster Highlighting Preclinical Data for Lead Program MOS101 at the American Association for Cancer Research (AACR)...
Mosaic Therapeutics will present preclinical data on its lead program MOS101—a combination of the next‑generation MDM2 antagonist ASTX295 and the FDA‑approved PARP inhibitor olaparib—at the AACR 2026 Annual Meeting. The poster focuses on BRCA2‑mutant, TP53‑wild‑type solid tumours and highlights the...
Pharma Pulse: A Rare Disease Drug Approval and the Evolving Scope of Pharmacy Practice
The FDA has broadened approval for Imcivree (setmelanotide), creating the first targeted therapy for acquired hypothalamic obesity and reporting an 18.4% placebo‑adjusted BMI reduction in Phase III trials. Parallel research shows that deploying pharmacy technicians as vaccine injectors dramatically improves uptake...
Why CMS Is Tightening ASP Reporting and What Manufacturers Must Get Right
CMS will require pharmaceutical manufacturers to submit the "reasonable assumptions" used to calculate their quarterly Average Sales Price (ASP) beginning in 2026. The move formalizes the estimation process that underlies ASP, covering rebates, bundled discounts, free‑goods programs, 340B sales and...
You Can’t Unsee This
A recent British Journal of Ophthalmology study found that users of Wegovy, the higher‑dose GLP‑1 weight‑loss injection, face a five‑fold increased risk of non‑arteritic anterior ischemic optic neuropathy (NAION), an eye‑stroke that can cause blindness. The condition occurs in roughly...
Latest TechBio News
Evotec SE announced that its Seattle CDMO, Just‑Evotec Biologics, has been selected by BARDA’s BioMaP‑Consortium for a multi‑year, up‑to‑$10 million program to optimize manufacturing of a monoclonal‑antibody cocktail against Ebola and Sudan viruses. The same day, Evotec disclosed that partner Bristol...
Top 5 Fastest Growing Pharma & Biotech Companies in Europe in 2026
A Financial Times analysis of Statista data identifies Europe’s five fastest‑growing pharma and biotech firms between 2021 and 2024. Italy’s Itaste Medical surged to €18.4 billion in sales, a 2,035% absolute growth, while the UK‑based Grow Group expanded cannabis‑based medicines to...
Dr. Yeadon Comments on "Ex Pfizer Chief Toxicologist: Toxicology Studies Sacrificed to Speed."
Dr. Michael Yeadon highlights testimony from former Pfizer Europe chief toxicologist Dr. Helmut Sterz, who claimed essential toxicology studies were omitted to accelerate approval of Pfizer‑BioNTech’s mRNA COVID‑19 vaccine. Sterz alleges the product lacked carcinogenicity and reproductive toxicity data, was...
Plastic Waste Transformed Into Parkinson’s Drug in Bioengineering First
Researchers at the University of Edinburgh have engineered bacteria to transform PET plastic waste into levodopa, a primary treatment for Parkinson’s disease. By inserting a seven‑gene, four‑step biosynthetic pathway into Escherichia coli, the team converted both industrial PET feedstock and...
Europa Biosite Introduces Rapid RNA Production Technologies
Europa Biosite has formed a strategic distribution partnership with Quantoom Biosciences to bring Quantoom’s Ntensify® mano and micro RNA production technologies to European researchers. The deal also anticipates future distribution of Quantoom’s Ncapsulate® LNP formulation kits. By adding rapid, high‑quality...
FDA Approves Expanded Indication for Imcivree as Treatment for Hypothalamic Obesity
Rhythm Pharmaceuticals' Imcivree (setmelanotide) received FDA approval as the first treatment for acquired hypothalamic obesity, expanding its indication to adults and children aged four and older. The Phase III TRANSCEND trial demonstrated a 15.8% mean BMI reduction at 52 weeks, an...
QPX7728
Xeruborbactam (QPX‑7728) is a broad‑spectrum β‑lactamase inhibitor designed to revive the activity of β‑lactam antibiotics against multidrug‑resistant Gram‑negative bacteria. Developed by Qpex Biopharma and Shionogi, the molecule targets both serine‑ and metallo‑β‑lactamases, addressing a key resistance mechanism. Preclinical data show...
Why Pharma Is Exploring Direct-to-Employer Benefit Models
Pharmaceutical manufacturers are re‑examining traditional PBM‑centric distribution by offering direct‑to‑employer drug purchasing models. Companies like Andel charge a per‑prescription transaction fee and eliminate administrative or per‑member fees, aiming to lower drug spend for employers. Their platform centralizes prescription intake, routes...
Oryon Cell Therapies Reports Phase 1b/2a Data Showing Sustained Motor Improvements in People with Parkinson’s Disease
Oryon Cell Therapies presented interim Phase 1b/2a data showing that its autologous dopaminergic neuron‑replacement therapy produced sustained motor improvements in Parkinson’s patients. Five participants experienced 29‑62% reductions in OFF‑state MDS‑UPDRS Part III scores over 6‑18 months, with continued gains beyond six months....
If Gene Therapies Are so Revolutionary, Why Does No One Want to Pay for Them?
Gene therapies promise one‑time cures for diseases like sickle‑cell and inherited blindness, but their price tags—often $1 million to $3 million per patient—clash with the U.S. insurance model. More than half of new cell and gene therapies face coverage restrictions because insurers...
Latent-Y: The Autonomous AI Agent for Drug Design at Scale
Latent Labs unveiled Latent‑Y, an autonomous AI agent that designs therapeutic antibodies from natural‑language prompts. Powered by the Latent‑X2 generative model, the platform compresses weeks of expert work into hours and can run multiple design campaigns in parallel. In three...
How Do Recent Actions From FDA Provide Insight to the Agency's Enforcement Posture?
The FDA’s Rare Disease Evidence Principles (RDEP) introduce flexible trial designs, allowing sponsors to use natural‑history data and novel biomarkers as endpoints. These guidances aim to accelerate approvals for rare‑disease therapies while maintaining safety as a top priority. However, analysts...
DEA Fine Tunes Power of Attorney and DEA-222 Requirements
On March 20, 2026, the DEA issued a technical amendment to its 2019 final rule that clarifies who may execute and revoke Power of Attorney documents for DEA Form 222 and who may sign the form itself. The amendment aligns...
Eli Lilly and Company (LLY) Expands Zepbound Access as Pricing Reforms Boost Long-Term Growth Outlook
Eli Lilly announced on March 16 that its obesity treatment Zepbound will be sold directly to consumers for $299 a month for the 2.5 mg dose through LillyDirect and major pharmacy chains. A new savings card locks that price nationwide for the KwikPen...
Prothena Partners Present Data Supporting Next Generation Treatments for Parkinson’s and Alzheimer’s Disease at AD/PD™ 2026
Prothena and its partners Roche and Bristol Myers Squibb presented late‑stage data on two neurodegenerative candidates at AD/PD™ 2026. Prasinezumab demonstrated a roughly two‑year delay in Parkinson’s disease progression, sustained motor benefits in the PADOVA open‑label extension, and favorable imaging and...
Dose as the Ultimate MPO Endpoint
Tristan Maurer’s Flash Talk framed dose as the definitive multiparametric optimization (MPO) endpoint for small‑molecule drug design. He argued that dose integrates exposure, pharmacology, and mechanism‑driven effects, making it the linchpin for balancing potency, ADME, and safety. The presentation highlighted...
DNA-Engineered Silver Nanoclusters Enable Precision Killing of Drug-Resistant Bacteria
A team led by Kirill Afonin at UNC Charlotte engineered programmable DNA scaffolds that organize silver nanoclusters into highly potent antimicrobial agents. The spatially arranged DNA‑AgNCs showed up to 78‑fold greater killing efficiency against ESKAPE pathogens and meningitis‑causing bacteria compared...